Download: Clinical Development of SE36 Malaria Vaccine-

Email address:

First name:

Last name:

Job title:

Company name:

Country:

I work for

Please specify your industry *

Mobile number:

What is your role?

Subscribe to VaccineNation Newsletter?

Unfortunately the document is not available at this current time, however if you leave your details we'll get it to you as soon as we can.

Please fill in all the information requested. It is very important you enter this information correctly so we can contact you with the document.

Remember my details Information

Remember my details

We place a 'cookie' on your computer so next time you visit us you don't need to fill in all these details

close »

Earlier this year at the World Vaccine Congress Asia 2013 Congress, Toshihiro Horii, Ph.D RIMD, Osaka University delivered the presentation: Malaria: Innovating prophylactic vaccine pipeline for tropical infectious diseases -Clinical Development of SE36 Malaria Vaccine.

The contents of this presentation is:

Structure of SERA5 protein and SE36 recombinant molecule

Correlation of anti-SE36 antibody levels with parasitemia in residents from the Solomon Islands

Sero-positive rate against N-terminal domain of SERA is very low in younger generations and increases with age

Clinical trials of BK-SE36 in Uganda

Phase 1b: Trial design

Administration site reactions

Immunogenicity of BK-SE36

Follow-up study

Vaccine efficacy

Non-Responder to BK-SE36

Responder to BK-SE36

Changes in antibody titer in responders ( >2 increase of titer by vaccination)

Correlation between vaccine response and reinfection

Nucleotide diversity of P. falciparum SERA5